Pharma: Page 12

  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Pharma reshoring

    Lilly expands US manufacturing build-out with $50B target

    The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry to reshore drug production.

    By Ned Pagliarulo • Feb. 26, 2025
  • A computer screen shows the Pfizer logo and stock price at the New York Stock Exchange
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Summit partners with Pfizer to study bispecific, ADC combinations

    The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially landscape-changing combinations.”

    By • Feb. 24, 2025
  • An illustration of beta amyloid plaques and tau in the brain Explore the Trendline➔
    Image attribution tooltip
    National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    Alzheimer's disease

    Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.

    By BioPharma Dive staff
  • People pass an office building with signage spelling Pfizer in New York City.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Pfizer names Patrizia Cavazzoni, former top FDA official, as chief medical officer

    Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida Habtezion.

    By Ned Pagliarulo • Feb. 24, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMA’s new chair

    The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a competing bid for Acelyrin and Intra-Cellular sales rose.

    By BioPharma Dive staff • Updated Feb. 24, 2025
  • A Pfizer sign sits outside the company's Ian C. Read Laboratories in Cambridge, Massachusetts, on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Pfizer stops selling hemophilia gene therapy, citing weak demand

    Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for the bleeding condition.

    By Ned Pagliarulo • Feb. 21, 2025
  • Corporate logos are seen outside on May 15, 2006, in Macclesfield, England.
    Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    AstraZeneca deepens China presence with FibroGen deal

    The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through government investigations into its business practices there. 

    By Kristin Jensen • Feb. 20, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Sanofi reaches consumer health deal; Supernus antidepressant fails study

    The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Ultragenyx secured a PDUFA date for its Sanfilippo gene therapy.

    By BioPharma Dive staff • Feb. 19, 2025
  • A closeup of an entryway that reads the Federal Trade Commission.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trump administration

    FTC retains stricter merger guidelines under Trump

    Agency chair Andrew Ferguson sent a memo to staff on Tuesday clarifying that Biden-era guidelines will remain in place — for now.

    By Rebecca Pifer Parduhn • Feb. 19, 2025
  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Vaccines

    GSK’s 5-in-1 meningococcal shot wins FDA approval

    Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through 25 years old.

    By • Updated Feb. 18, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Neumora shakes up its C-suite; Biogen cuts early-stage pipeline

    Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager hit a setback for its ALS gene therapy.

    By BioPharma Dive staff • Feb. 13, 2025
  • Robert F. Kennedy Jr. sitting with his name printed in front of a microphone in front of him with his arm extended besides him while speaking in a room with government officials in the background.
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip
    Trump administration

    RFK Jr. confirmed by Senate as health secretary

    All but one Senate Republican voted for Kennedy, a controversial vaccine critic whose embrace of the “Make America Healthy Again” movement helped him win one of the most powerful jobs in Washington.

    By , Emily Olsen • Feb. 13, 2025
  • A close up shot of glasses filled with liquid held close together for a toast.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    New study offers hints of GLP-1 drugs’ potential in curbing alcohol cravings

    A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed to establish a conclusive benefit.

    By • Feb. 12, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK

    The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority review on a key drug and Third Harmonic restructured.

    By BioPharma Dive staff • Feb. 11, 2025
  • A 3D visualization of red blood cells traveling through a blood vessel.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novartis pays $925M to reel in a startup it helped launch

    The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed to the Blackstone-backed startup six years ago.

    By • Feb. 11, 2025
  • Microscopic cancer cells
    Image attribution tooltip

    stock.adobe.com/Ravi

    Image attribution tooltip
    Sponsored by Quest Diagnostics

    The role of diagnostics in advancing antibody-drug conjugates

    Antibody-drug conjugates (ADCs) are revolutionizing oncology, but success requires precision diagnostics.

    By Thomas P. Salvin, MD, MBA, Chief Clinical Officer, Molecular Diagnostics, Quest Diagnostics • Feb. 10, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Bain buys Mitsubishi pharma unit; Bausch + Lomb deal talks come up empty

    The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t yet found a suitor and a pair of biotechs cut staff.

    By BioPharma Dive staff • Feb. 7, 2025
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Bristol Myers, bracing for key patent losses, deepens cost-cutting plan

    The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies across multiple areas of the business,” its CFO told analysts on a conference call. 

    By • Feb. 6, 2025
  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Eli Lilly’s earnings, shares lifted by obesity drug sales

    The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for its weight loss medicines in January.

    By Kristin Jensen • Feb. 6, 2025
  • Bottles of Bristol Myers Squibb's Cobenfy, a new drug for schizophrenia, are arranged in this photo illustration.
    Image attribution tooltip
    Permission granted by Bristol Myers Squibb
    Image attribution tooltip
    Brain drug revival

    Bristol Myers gives first peek at closely watched launch of schizophrenia drug

    Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the fourth quarter and around 1,000 prescriptions weekly by late January.

    By • Feb. 6, 2025
  • Pfizer's logo cast in metal.
    Image attribution tooltip
    Jeenah Moon via Getty Images
    Image attribution tooltip

    Pfizer taps former Novartis exec to lead cancer drug push

    The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow sales in the years ahead. 

    By • Feb. 6, 2025
  • Human respiratory syncytial virus virions are shedding from the surface of human lung cells.
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2017). "Human Respiratory Syncytial Virus" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip

    GSK, Pfizer sales of RSV shots slow as vaccination rates ebb

    Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.

    By • Feb. 5, 2025
  • A Novo Nordisk sign is seen on the side of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novo outlines new late-stage study of obesity drug CagriSema

    CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer duration in the new trial.

    By • Feb. 5, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Amgen obesity drug on hold; Regeneron sets first dividend

    Elsewhere, cell therapy developer Turnstone Biologics announced a second round of layoffs and plans to explore “strategic alternatives.”  

    By Ned Pagliarulo • Feb. 5, 2025
  • A vial of Merck & Co.'s human papillomavirus vaccine Gardasil.
    Image attribution tooltip
    Joe Raedle via Getty Images
    Image attribution tooltip

    Merck shares tumble as company pauses Gardasil shipments to China

    Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

    By • Feb. 4, 2025
  • A Pfizer logo sits atop the entrance of the company's Ian C. Read Laboratories in Cambridge, Massachusetts, on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Pfizer drug acquired in $11B buyout confirms benefit in colon cancer

    The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval — boosting an oncology portfolio Pfizer is looking to for revenue growth.

    By • Feb. 3, 2025